Albrecht K.,Deutsches Rheuma Forschungszentrum Berlin
Deutsche Medizinische Wochenschrift | Year: 2014
Patients with rheumatoid arthritis (RA) often have one or more comorbid conditions. The prevalence of comorbidities increases with age and disease duration. Comorbidities influence the outcome of RA and limit therapeutic options. Besides suppressing disease activity of RA, screening and tight control of existing comorbidities is essential to avoid further damage. A close cooperation between general practitioners, rheumatologists and attending specialists is important for a successful treatment, taking into account the complex interaction of RA and its comorbidities. Source
Agency: Cordis | Branch: FP7 | Program: MC-IEF | Phase: FP7-PEOPLE-2012-IEF | Award Amount: 168.79K | Year: 2013
More than 5 million people in Europe live with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). Both diseases are characterized by chronic inflammation partially mediated by inappropriate T cell response. Effector T-cell responses can be modulated by competing positive or negative costimulatory signals, and dysregulated balance between these signals may lead to chronic autoimmune inflammation. In mice, within the CD4\ T cell population, the expression of NKG2D is primarily associated with pathological conditions and the administration of blocking anti-NKG2D antibodies ameliorated the disease in mouse models of arthritis and IBD. Therefore the aim of my project proposal is to clarify the role of NKG2D receptor signalling in CD4\ T cell biology and in the pathogenesis of autoimmune diseases. My work will implement mouse models to study the specific impact of NKG2D expressed on CD4\ T cells in the priming, formation and maintainance of memory of CD4\ T cells and their cytokine profile during homeostasis as well as in preclinical models of IBD and RA. Moreover, by global analysis of human NKG2D\ CD4\ T cells from the sites of inflammation, we aim to better understand the possible role of NKG2D in driving inflammatory responses in IBD and RA patients. By combining these approaches, we intend to get further insights into the role of NKG2D in the regulation of autoimmune diseases and to identify strategies to possibly ameliorate tissue damage and dampen inflammation.
Deutsches Rheuma Forschungszentrum Berlin | Date: 2011-10-12
The invention relates to a system for acquiring discontinuous emission spectra data, whereby the data is analyzed by a multivariate statistic model or equivalent model, such as principal component analysis and the use of the system for flow cytometry.
Deutsches Rheuma Forschungszentrum Berlin | Date: 2010-02-16
The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells.
Deutsches Rheuma Forschungszentrum Berlin and RAS Engelhardt Institute of Molecular Biology | Date: 2013-10-28
The invention relates to isolated bispecific affinity reagents, such as antibodies or antibody fragments that bind TNF and a marker molecule for macrophages and/or neutrophils. The affinity reagents of the invention enable pathogenic sub-populations of TNF to be neutralised, whilst protective sub-populations of TNF are not affected.